15 alternatives ranked by AI visibility score. Category: AI Drug Discovery.
Full-stack AI biologics company raised $787M in Mar 2026 backed by Sanofi, Pfizer/Hillhouse, and DST Global; $2.56B Sanofi collaboration signed Jan 2026; platform generates 40+ AI-designed protein the...
Iambic Therapeutics was founded in 2019 with the mission of applying AI-driven drug discovery to oncology — one of the most complex and high-value areas of pharmaceutical developme
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clini
Eikon Therapeutics is a drug discovery company that went public on Nasdaq in February 2026 (ticker: EIKN) with a $381 million IPO, armed with a proprietary RESOLFT super-resolution
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (
Xaira Therapeutics is an AI-powered drug discovery company launched from stealth in April 2024 with $1 billion in committed capital. Headquartered in South San Francisco, incubated
Converge Bio is an Israeli AI drug discovery company using machine learning to design and optimize small molecule therapeutics across a broad portfolio of programs. Founded by a te
Isomorphic Labs is an Alphabet company spun out of Google DeepMind to apply AI to the full drug discovery pipeline, from target identification through molecular design and clinical